MX2023001540A - Vacunas contra el cancer y metodos de tratamiento que las utilizan. - Google Patents
Vacunas contra el cancer y metodos de tratamiento que las utilizan.Info
- Publication number
- MX2023001540A MX2023001540A MX2023001540A MX2023001540A MX2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A MX 2023001540 A MX2023001540 A MX 2023001540A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treatment
- same
- cancer vaccines
- vaccine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000009566 cancer vaccine Methods 0.000 title 1
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 101000655350 Canis lupus familiaris Telomerase reverse transcriptase Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención proporciona una vacuna que comprende una molécula de ácido nucleico que codifica un antígeno de telomerasa transcriptasa inversa de perro (dTERT), así como métodos para utilizar la vacuna para inducir una respuesta inmunitaria contra TERT y para tratar cáncer en un mamífero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291601P | 2016-02-05 | 2016-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001540A true MX2023001540A (es) | 2023-03-08 |
Family
ID=59500919
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009506A MX2018009506A (es) | 2016-02-05 | 2017-02-03 | Vacunas contra el cáncer y métodos de tratamiento que las utilizan. |
MX2023001540A MX2023001540A (es) | 2016-02-05 | 2018-08-03 | Vacunas contra el cancer y metodos de tratamiento que las utilizan. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009506A MX2018009506A (es) | 2016-02-05 | 2017-02-03 | Vacunas contra el cáncer y métodos de tratamiento que las utilizan. |
Country Status (10)
Country | Link |
---|---|
US (3) | US11007255B2 (es) |
EP (1) | EP3411122A4 (es) |
JP (1) | JP7123800B2 (es) |
KR (1) | KR20180108793A (es) |
CN (2) | CN108883312B (es) |
AU (2) | AU2017214656B2 (es) |
BR (1) | BR112018015893A2 (es) |
CA (1) | CA3013718C (es) |
MX (2) | MX2018009506A (es) |
WO (1) | WO2017136758A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3064890A1 (en) * | 2017-05-26 | 2018-11-29 | The Wistar Institute Of Anatomy And Biology | Dtert vaccines and methods of treatment using the same |
EP3703734A1 (en) | 2017-10-31 | 2020-09-09 | Pantarhei Bioscience B.V. | Immunotherapeutic methods for treating and/or preventing lung cancer |
EP3723798A4 (en) * | 2017-12-13 | 2021-11-17 | Inovio Pharmaceuticals, Inc. | ANTI-BORIS CANCER VACCINES AND USES |
WO2021259963A1 (en) | 2020-06-23 | 2021-12-30 | Pandora Endocrine Innovation B.V. | Immunization against wnt4 for treatment and prophylaxis of breast cancer |
EP4419122A1 (en) | 2021-10-19 | 2024-08-28 | Sciencemed Spólka Z Ograniczona Odpowiedzialnoscia | Male contraception |
WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
NZ262582A (en) | 1993-01-26 | 1997-10-24 | David B Weiner | Compositions and methods for delivery of genetic material |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
DE69835761T2 (de) | 1997-04-03 | 2007-09-13 | Electrofect As. | Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
CZ299473B6 (cs) | 1997-06-30 | 2008-08-06 | Rhone-Poulenc Rorer S. A. | Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva |
EP2428249B1 (en) | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20040175727A1 (en) | 2002-11-04 | 2004-09-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
CA2567324C (en) | 2003-05-30 | 2012-01-03 | Advisys, Inc. | Devices and methods for biomaterial production |
CN105132439A (zh) * | 2006-07-28 | 2015-12-09 | 宾夕法尼亚大学托管会 | 改进的疫苗及其使用方法 |
BRPI0719865A2 (pt) * | 2006-10-12 | 2016-03-15 | Angeletti P Ist Richerche Bio | molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer |
PT2066399T (pt) | 2006-10-17 | 2019-01-11 | Inovio Pharmaceuticals Inc | Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos |
PT2153260T (pt) | 2007-05-23 | 2017-04-24 | Vgxi Inc | Composição que compreende uma alta concentração de moléculas biologicamente ativas e processos de preparação da mesma |
WO2013019603A2 (en) * | 2011-07-29 | 2013-02-07 | Inovio Pharmaceuticals, Inc. | Linear expression cassettes and uses thereof |
US11419925B2 (en) | 2013-03-15 | 2022-08-23 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
US10138488B2 (en) * | 2013-03-28 | 2018-11-27 | Invectys | Cancer vaccine for dogs |
US10398769B2 (en) * | 2013-08-06 | 2019-09-03 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
CA3064890A1 (en) * | 2017-05-26 | 2018-11-29 | The Wistar Institute Of Anatomy And Biology | Dtert vaccines and methods of treatment using the same |
-
2017
- 2017-02-03 BR BR112018015893A patent/BR112018015893A2/pt active Search and Examination
- 2017-02-03 KR KR1020187025572A patent/KR20180108793A/ko active Search and Examination
- 2017-02-03 MX MX2018009506A patent/MX2018009506A/es unknown
- 2017-02-03 AU AU2017214656A patent/AU2017214656B2/en active Active
- 2017-02-03 US US16/075,527 patent/US11007255B2/en active Active
- 2017-02-03 JP JP2018540794A patent/JP7123800B2/ja active Active
- 2017-02-03 CA CA3013718A patent/CA3013718C/en active Active
- 2017-02-03 CN CN201780020641.5A patent/CN108883312B/zh active Active
- 2017-02-03 CN CN202410352664.8A patent/CN118184761A/zh active Pending
- 2017-02-03 EP EP17748295.7A patent/EP3411122A4/en active Pending
- 2017-02-03 WO PCT/US2017/016557 patent/WO2017136758A1/en active Application Filing
-
2018
- 2018-08-03 MX MX2023001540A patent/MX2023001540A/es unknown
-
2021
- 2021-04-09 US US17/226,633 patent/US11801288B2/en active Active
-
2022
- 2022-11-17 AU AU2022271441A patent/AU2022271441A1/en active Pending
-
2023
- 2023-09-22 US US18/472,640 patent/US20240082374A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2018009506A (es) | 2019-05-06 |
CN108883312B (zh) | 2024-04-09 |
BR112018015893A2 (pt) | 2019-03-06 |
US11801288B2 (en) | 2023-10-31 |
EP3411122A1 (en) | 2018-12-12 |
WO2017136758A1 (en) | 2017-08-10 |
US20190038729A1 (en) | 2019-02-07 |
KR20180108793A (ko) | 2018-10-04 |
AU2017214656B2 (en) | 2022-08-25 |
AU2017214656A1 (en) | 2018-08-30 |
CN118184761A (zh) | 2024-06-14 |
EP3411122A4 (en) | 2019-10-23 |
US20240082374A1 (en) | 2024-03-14 |
US20210268084A1 (en) | 2021-09-02 |
AU2022271441A1 (en) | 2022-12-22 |
CN108883312A (zh) | 2018-11-23 |
CA3013718A1 (en) | 2017-08-10 |
CA3013718C (en) | 2023-09-26 |
US11007255B2 (en) | 2021-05-18 |
JP2019508403A (ja) | 2019-03-28 |
JP7123800B2 (ja) | 2022-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
PH12019500628A1 (en) | Anti-cd27 antibodies | |
PH12018502112A1 (en) | Anti-tim-3 antibodies and compositions | |
MX2023014569A (es) | Anticuerpos anti-sirpa. | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
NZ739750A (en) | Anti-tigit antibodies and methods of use | |
EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
MX2017001406A (es) | Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva. | |
WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
MX2017002862A (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso. | |
CL2017000625A1 (es) | Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos | |
MX2017011991A (es) | Terapia virica con una combinacion de anticuerpos. | |
BR112017025533A2 (pt) | método para tratar câncer em um paciente humano | |
UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
MX2020004376A (es) | Uso de inhibidores de nox para el tratamiento de cancer. | |
PH12018501170A1 (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
MX2022009171A (es) | Composiciones para el tratamiento de dermatitis atopica canina y sus usos. |